An iron-based oxide magnetic particle powder has a narrow particle size distribution a small content of fine particles that do not contribute to magnetic recording characteristics, and a narrow coercive force distribution, to enhance magnetic recording medium density. Neutralizing an aqueous solution containing a trivalent iron ion and an ion of the metal substituting a part of the Fe sites by adding an alkali to make pH of 1.5 or more and 2.5 or less, adding a hydroxycarboxylic acid, and further neutralizing by adding an alkali to make pH of 8.0 or more and 9.0 or less are performed at 5° C. or more and 25° C. or less. A formed iron oxyhydroxide precipitate containing the substituting metal element is rinsed with water, then coated with silicon oxide, and then heated thereby providing e-type iron-based oxide magnetic particle powder. The rinsed precipitate may be subjected to a hydrothermal treatment.

A core-shell particle includes: a core including an iron oxyhydroxide compound represented by Formula A.sup.3.sub.a3Fe.sub.1−a3OOH (in which A.sup.3 represents at least one metal element other than Fe, and a3 satisfies 0<a3<1) or at least one iron oxide compound selected from the group consisting of Fe.sub.2O.sub.3, a compound represented by Formula A.sup.1.sub.a1Fe.sub.2−a1O.sub.3 (in which A.sup.1 represents at least one metal element other than Fe, and a1 satisfies 0<a1<2), Fe.sub.3O.sub.4, and a compound represented by Formula A.sup.2.sub.a2Fe.sub.3−a2O.sub.4 (in which A.sup.2 represents at least one metal element other than Fe, and a2 satisfies 0<a2<2); and a shell which covers the core and includes a polycondensate of a metal alkoxide.

The present invention relates to methods and products for isolating nucleic acids from samples containing biological material. In particular, the present invention relates to silica-coated magnetic particles, processes for their preparation and their use in methods of isolating nucleic acids samples containing biological material.

A magnetic particle is disclosed. The magnetic particle comprises a magnetic material having a maximum field strength in a range of from about 20 emu/g to about 250 emu/g and a remanence in a range of from about 0 emu/g to about 30 emu/g. The magnetic particle further comprises an outer surface containing a ligand. The ligand interacts with an analyte of interest in the sample solution.

A method of manufacturing a chiral nano-structure having chirality using a magnetic field according to one embodiment of the present disclosure includes a magnetic field forming operation that forms a magnetic field; a particle arranging operation that arranges at least two nanoparticles in the magnetic field; and a magnetic field adjusting operation that adjusts at least one of a magnetic flux density, a magnetization direction, and a spatial range of the magnetic field, in which in the magnetic field adjusting operation, the arrangement of the nanoparticles arranged in the magnetic field is aligned to correspond to a structure of the magnetic field, and the entire structure is formed as a nano-structure having chirality.

As a magnetoplasmonic particle that can have physical reactability, that is, arrangement variability to a magnetic field to implement an immediate self-assembly property, can be manufactured as a three-dimensional structure through a significantly simplified process compared to the conventional one based on this arrangement variability due to the application of the magnetic field, can be used in various technical fields because an additional change or adjustment of a geometrical of this three-dimensional structure is easy, there is provided the magnetoplasmonic particle including a core-shell particle including a core and a shell surrounding at least a part of a surface of the core and including a component different from a component of the core, and having the arrangement variability due to the application of the magnetic field.

A core-shell structure supported catalyst and a preparation method and use thereof are disclosed. The core-shell structure supported catalyst includes a core-shell structure carrier and platinum supported on the surface of the core-shell structure carrier, wherein the core-shell structure carrier includes a ferroferric oxide nanoparticle core and a nitrogen-doped carbon shell, and a molar ratio of the ferroferric oxide nanoparticle core to platinum is 1:(0.03-0.3).

A biomagnetic microsphere and a preparation method and a method for protein isolation and purification therefor. The outer surface of a magnetic microsphere body of the biomagnetic microsphere has at least one liner polymer with a branched chain; one end of the linear polymer with a branched chain is covalently coupled to the outer surface of the magnetic microsphere body, and other parts are free on the outer surface of the magnetic microsphere body; a backbone of the linear polymer is a polyolefin backbone, and no cross-linking agent is required in the backbone forming process of the linear polymer. The prepared biomagnetic microsphere can implement efficient elution of target proteins and effectively reduce the retention time and retention ratio of the target proteins, and it is easy to operate and widely used.

Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

This invention provides mass spectrometry (MS) compatible nanomaterials for the selective capture and enrichment of low abundance proteins as well as MS analysis of different proteoforms of proteins, particularly cardiac proteins and different proteoforms of cardiac troponin I (cTnI) arising from post-translational modifications and sequence variations. The surface of superparamagnetic nanoparticles is functionalized with probe molecules that specifically bind to the desired protein. In an embodiment, the nanoparticles are functionalized with probe molecules having high affinity and selectivity for cTnI within the human cardiac troponin complex. This allows for MS-analysis and characterization of cTnI proteoforms from human heart tissue lysates and human blood or serum samples, and provides an accurate assay for detection of cTnI with molecular details. Such assays are useful for accurate diagnosis of acute coronary syndrome and chronic diseases, including acute myocardial infarction and other cardiac injuries, as well as risk stratification and outcome assessment for patients.